Month: January 2022

The Company to commit more R&D resources to help drive down the cost of producing green hydrogen SANTA CLARITA, Calif., Jan. 19, 2022 (GLOBE NEWSWIRE) — NewHydrogen, Inc. (OTC:NEWH), a developer of a breakthrough green hydrogen generator that uses renewable energy to produce low-cost green hydrogen, today announced that it has expanded its green hydrogen development plan. The company also will commit more research and development resources to help drive down the cost of producing green hydrogen. “An electrolyzer — the primary component of a hydrogen generator — is still very expensive,” said David Lee, CEO of NewHydrogen. “We have made great progress with our existing technology developments to replace and reduce the expensive rare earth materials, which represent a significant cost factor. Now, we will widen our focus to...

COPENHAGEN, Denmark, January 19, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today the appointment of Russell Thirsk as Executive Vice President and Chief Operating Officer, effective from April 1, 2022. Mr. Thirsk will take over this position from Henrik Birk, who has decided to seek new challenges outside Bavarian Nordic. The timing allows a period of handover from Henrik Birk to ensure a smooth transition. Mr. Thirsk joins Bavarian Nordic from GSK, where he has served as Head of Operations at GSK Vaccines in Belgium since 2016, a role he assumed after GSK’s acquisition of Novartis’ vaccine business, where he served for more than two decades, holding leadership roles of increasing responsibility in vaccine manufacturing operations across various geographies. Mr. Thirsk holds a Master of Chemical Engineering from University of Nottingham. “I...

Results of European study potentially incorporated into U.S. regulatory strategy for FDA approval Opportunity for ColoAlert to become the gold standard at-home screening test for colorectal cancer BERKELEY, Calif. and MAINZ, Germany, Jan. 19, 2022 (GLOBE NEWSWIRE) — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today it has formally contracted with DCN Dx, a leading international developer of point-of-care diagnostics, and provider of comprehensive product development services. An integral part of the engagement will be the role of Emily Friedland, Vice President of Clinical Research at DCN Dx, who will spearhead the preparation and initiation of Mainz’s European centric clinical study to evaluate the potential...

Oslo, 19 January 2022 Ensurge Micropower ASA (OSE: ENSU, OTCQB: ENMPY) today announced the signing of a customer agreement with a leader and innovator in the digital health market. Under the terms of the agreement, Ensurge will deliver customized Ensurge solid-state microbatteries for production starting in the fourth quarter of 2022.  Ensurge is receiving several milestone-based payments for the customization. “This win is a significant achievement for Ensurge as it allows us to tap into the exploding digital health and remote patient monitoring markets,” said Ensurge CEO Kevin Barber. “Ensurge microbatteries bring unique value propositions to these devices.  Flexible form factors, fast charging, ability to support high current draw and wider temperature range differentiate Ensurge microbattery in addition to the higher...